GENE ONLINE|News &
Opinion
Blog

2022-06-06| M&A

BMS Buys Turning Point Therapeutics For $4.1 Billion, Bringing In Lung Cancer Drug

by Joy Lin
Share To

Bristol Myers Squibb is back in the M&A game, nearly two years after its $13.1 billion acquisition of MyoKardia. This time, the drug giant is buying precision oncology company Turning Point Therapeutics for $4.1 billion, or $76 per share in cash. The acquisition gives repotrectinib, an investigational ROS1/NTRK inhibitor for non-small cell lung cancer (NSCLC) patients who test positive for ROS1. 

Repotrectinib is expected to be approved in the US in the second half of 2023 and become a new standard of care for patients with ROS1 NSCLC in the first-line setting, said BMS. The drug is expected to contribute to the company’s non-GAAP earnings in 2025. 

 

Related article: Everest and Gilead Announce Positive Phase 3 Results of Breast Cancer Drug

 

ROS1/NTRK Rival to Pfizer, Roche

 

Repotrectinib is a tyrosine kinase inhibitor (TKI) targeting ROS1 and NTRK oncogenic drivers of NSCLC and other advanced solid tumors. The drug has three Breakthrough Therapy Designations (BTD) from the US FDA in ROS1 or NTRK NSCLC, as well as an Orphan Drug Designation and four Fast Track Designations. 

According to Turning Point, patients treated with repotrectinib in the Phase 1/2 Trident-1 clinical study showed longer duration of response compared to existing ROS1 drugs in first-line NSCLC.

By acquiring reprotrectinib, BMS is setting itself up against Roche’s Rozlytrek (entrectinib) and Pfizer’s Xalkori (crizotinib), ROS1 inhibitors that have already been approved by the FDA for ROS1 NSCLC. 

With brain metastases being a common problem in patients with metastatic NSCLC, the ability of repotrectinib to penetrate the central nervous system (CNS) may become its main draw against entrectinib and crizotinib, the latter of which is limited by poor penetration in the CNS. Repotrectinib has shown efficacy in penetrating the CNS in preclinical studies, which may allow it to contend with the CNS-penetrant entrectinib. 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
CHMP Recommends Approval for Bristol Myers Squibb First-Line Treatment for Advanced Melanoma
2022-07-25
Cancer Research UK and Sosei Heptares Set for First Human Trial of EP4 Antagonist
2022-07-22
Orion Collects $290 Million From Merck in Prostate Cancer Development Collaboration
2022-07-14
LATEST
Vaccine Protecting Against 20 Different Pneumococcal Infections Proves Effective in Trial
2022-08-12
FDA Approves Roche’s Established Antiviral For Children Aged Five Or Older
2022-08-12
Novartis Reported Two Deaths Following Zolgensma Gene Therapy
2022-08-12
Extreme Climate Change Is Aggravating Infectious Diseases!
2022-08-11
In Response to Expanding Monkeypox Outbreak, FDA Approves Emergency Use of JYNNEOS Vaccine
2022-08-11
Potential $1 billion Acquisition of TeneoTwo by AstraZeneca comes to Fruition
2022-08-11
Gene Repair Therapy: First Patient Dosed With New Treatment for Sickle Cell Disease
2022-08-11
EVENT
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-20
Cell & Gene Therapy USA 2022
Virtual
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-21
RESI Boston
Boston
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!